Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Investor Presentation (November 2020)
26 slides from Genocea Biosciences's investor presentation, Nov 18, 2020
Slide 1: Better personalized cancer immunotherapies through better neoantigen targeting
Better personalized cancer immunotherapies through better neoantigen targeting November 2020
Slide 2: Disclaimer
This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning our possible or ass
Slide 3: Genocea at a glance
Genocea at a glance Revolutionary antigen discovery platform TARGETS MATTER GEN-009 GEN-011 Neoantigen Neoantigen Differentiated vaccine cell therapy clinical-stage immunotherapies Differentiated Ph 1/2a Accruing patients in immune response, clinical Ph 1/2a trial responses 3
Slide 4: ATLAS: high throughput platform for true antigen selection
ATLAS: high throughput platform harnessing the immune system for true antigen selection Tumor NGS biopsy analysis Unique Bacterial plasmids for vectors Autologous every expressing each dendritic cell candidate candidate neoantigen Autologous T cell Blood sample Only ATLAS can identify InhibigensTM –
Slide 5: Inhibigen identification and exclusion is critical to ensure therapeutic efficacy
Inhibigen identification and exclusion is critical to ensure therapeutic efficacy 1,600 Adjuvant only 1,000 ) 1,400 Protective vaccine 1. Therapeutic mouse vaccination Adjuvant only 3 ) 3 1,200 Protective vaccine + Inhibigen with a pool of ATLAS-identified 800 Inhibigens + Adjuvant Inhibigens drives
Slide 6: ATLAS has powerful advantages over other neoantigen selection approaches
ATLAS has powerful advantages over other neoantigen selection and targeting approaches Benefits ATLAS advantages Identifies all true neoantigens: i.e., all surface-presented peptides eliciting anti- tumor T cell responses. Delivers cell therapies and vaccines that minimize tumor escape Enables great
Slide 7: GEN-009 Neoantigen Vaccine
GEN-009 Unprecedented immune responses; Neoantigen Vaccine Emerging clinical efficacy 7
Slide 8: Simple, scalable production and delivery
Simple, scalable production and delivery 8
Slide 9: GEN-009 Phase 1/2a trial design
GEN-009 Phase 1/2a trial design Part A • Vaccine monotherapy in patients with no evidence of disease • Multiple tumor types with CPI approval • Objectives: safety, immunogenicity • Status: all patients in long-term follow-up • Part B • Combination of GEN-009 and standard-of-care PD-1-based regimens
Slide 10: Strong immune responses and recurrence-free survival in Part A
Strong immune responses and recurrence-free survival in Part A Immune response frequency % neoantigens with immune responses 60% 99% Best peer results1 GEN-009 Achieved in combination Monotherapy with CPI Potential patient benefits Response breadth to prevent tumor escape 0 6 12 18 24 1 Sahin, et al
Slide 11: GEN-009 Part B is being studied in two distinct patient groups
GEN-009 Part B is being studied in two distinct patient groups 1. Checkpoint-sensitive / controlled GEN-009 dosing +/- prior therapy SOC and GEN-009 manufacture Biopsy Enroll Progression and GEN-009 dosing salvage treatment 2. Checkpoint-resistant SOC Therapy Melanoma: nivo monotherapy or nivo + ipi
Slide 12: Part B trial design enables assessment of vaccine specific contribution
Part B trial design enables assessment of vaccine specific contribution to clinical responses Each patient can serve as own control , Pre-Vaccination Post-Vaccine Dose 1 PD (+20%) @Scan Baseline © Ss PR (-30%) o 3 “"" etfectattributable to vaccine % Change in Target Lesion Sum be & & $s Vaccine Dose
Slide 13: Compelling signal of response in checkpoint-sensitive patients
Compelling signal of response in checkpoint-sensitive patients GEN-009 responses 1 CR and 2 PR of 7 evaluable Overall responses 2/9 (22%) with CR 4/9 (67%) with PR 2/9 (22%) with SD 7/9 (78%) progression-free 13
Slide 14: Early evidence of stabilization in checkpoint-resistant patients
Early evidence of stabilization in checkpoint-resistant patients Investigator iRECIST read after GEN-009 5/7 disease control 1 patient with possible pseudo-progression 14
Slide 15: GEN-009 continues to demonstrate unparalleled immune responses
GEN-009 continues to demonstrate unparalleled immune responses + + 900 PBMC 900 CD4 350 CD8 ~35,000/million ~30,000/million ~10,000/million 800 IFN-gamma 800 IFN-gamma IFN-gamma 300 TNF-alpha TNF-alpha TNF-alpha 700 cells T 700 cells T + + 250 600 600 500 500 200 400 400 150 300 300 100 200 200 IVS
Slide 16: GEN-009: Delivering on the promise of neoantigen therapies
GEN-009: Delivering on the promise of neoantigen therapies Compelling early signal persists with longer follow-up Clear anti-tumor activity “Targets matter” Highly differentiated immunogenicity results Powerful readthrough to GEN-011 ATLAS enables unique breadth and specificity 16
Slide 17: GEN-011 Neoantigen T cell Therapy
GEN-011 Potential best-in-class solid tumor Neoantigen T cell Therapy adoptive T cell therapy 17
Slide 18: TIL therapy: Current gold standard for solid tumor cell therapy
TIL therapy: Current gold standard for solid tumor cell therapy Tumor-infiltrating lymphocyte (TIL) 2,3,4 CAR-T therapy Unproven in solid tumors TCR-transduced (TCR-T) Limited clinical validation HLA-limited Durable efficacy Potential safety concerns1 in checkpoint-refractory patients 1. Linette et
Slide 19: GEN-011: A new category of solid tumor cell therapy
GEN-011: A new category of solid tumor cell therapy: Neoantigen-targeted Peripheral T cells (NPTs) Peripheral blood (leukopak) GEN-011 Up to 30 neoantigens Neoantigen-specific cell expansion in fully closed single-use vessels NPTs: Non-engineered, neoantigen-specific 19
Slide 20: GEN-011 overcomes limitations of other solid tumor cell therapies
GEN-011 overcomes limitations of other solid tumor cell therapies GEN-011 Advantages Features GEN-011 TIL TCR-T Targets up to 30 neoantigens to limit tumor escape Avoids Inhibigens that may be detrimental to clinical response Greater efficacy Includes CD4+ and CD8+ neoantigen-specific T cells Non-ex
Slide 21: GEN-011 provides unparalleled breadth of neoantigen coverage
GEN-011 provides unparalleled breadth of neoantigen coverage GEN-011 targets up to 30 neoantigens Recent conventional TIL data show responses to an average 89% of 6% of the predicted neoantigens2 Recent selected TIL data show successful amplification to only 4% of antigens included in the process1 G
Slide 22: GEN-011 delivers billions of NPTs with desired phenotype
Additionally, GEN-011 delivers billions of NPTs that are: The desired memory phenotype Highly neoantigen-specific 96% Antigen Specific 100 75 50 % Frequency 25 0 Activation Marker 2 Naive Terminal Memory memory (Cm+Em) Activation Marker 1 Powerfully cytolytic against their targets More active and po
Slide 23: Robust and rapidly scalable manufacturing process
Robust and rapidly scalable manufacturing process with fully closed single-use technology Peripheral blood Phenotypic (leukopak) GEN-011 Process cell sort Peripheral blood from every patient, dramatically T cells expanding accessible patient population Up to 30 verified Robust process designed to de
Slide 24: TITAN trial: Phase 1/2a study of GEN-011
Trial Objectives TITAN trial: Phase 1/2a study of GEN-011 in patients with CPI–resistant solid tumors Targeted indications Cohort A Trial objectives Patients with immune Multiple low dose • Safety responsive tumors that have (up to 12 patients) • Clinical activity not achieved an adequate • No lymph
Slide 25: GEN-011: Transforming neoantigen T cell therapy for solid tumors
GEN-011: Transforming neoantigen T cell therapy for solid tumors CD8+ and CD4+ T cells targeting up to 30 neoantigens Peripheral blood enabling greater accessibility, activity and durability Robust and rapidly scalable manufacturing process 25
Slide 26: Contact details
NASDAQ: GNCA 100 Acorn Park Drive Cambridge, MA 02140 USA +1 617.876.8191 www.genocea.com 26
Genocea Biosciences — Investor Presentation (November 2020) on 6ix